Review Compares GLP-1 Agonists and SGLT2 Inhibitors for Urolithiasis | Retatrutide News

The review compared SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors for urolithiasis risk. This is relevant for understanding the safety profiles...
Clinical Trials · October 14, 2026